Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (111-120 of 192) with videos related to

Pageof 20
Sort By:
International Journal of Antimicrobial Agents|January 28, 2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO RegistryFrancesco Saladini, Federica Giammarino, Franco Maggiolo, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2009
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weightingMaurizio Zazzi, Mattia Prosperi, Ilaria Vicenti, et al.
AIDS Research and Human Retroviruses|October 1, 2020
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian CohortArturo Ciccullo, Gianmaria Baldin, Vanni Borghi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2024
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort studySergio Lo Caputo, Mariacristina Poliseno, Alessandro Tavelli, et al.
Le Infezioni in Medicina|December 18, 2019
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort studyGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2020
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular diseaseAna Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, et al.
Journal of Global Antimicrobial Resistance|January 30, 2025
Assessing the utilization of HIV genotype resistance testing: Insight from Italian Infectious Diseases UnitsAndrea De Vito, Antonia Bezenchek, Rossana Scutari, et al.
Antiviral Therapy|September 24, 2016
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohortAmedeo F Capetti, Gaetana Sterrantino, Maria V Cossu, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 26, 2020
Marked decrease in acquired resistance to antiretrovirals in latest years in ItalyAlessia Lai, Marco Franzetti, Annalisa Bergna, et al.
Pageof 20

Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
International Journal of Antimicrobial Agents|January 28, 2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO RegistryFrancesco Saladini, Federica Giammarino, Franco Maggiolo, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2009
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weightingMaurizio Zazzi, Mattia Prosperi, Ilaria Vicenti, et al.
AIDS Research and Human Retroviruses|October 1, 2020
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian CohortArturo Ciccullo, Gianmaria Baldin, Vanni Borghi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 6, 2024
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort studySergio Lo Caputo, Mariacristina Poliseno, Alessandro Tavelli, et al.
Le Infezioni in Medicina|December 18, 2019
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort studyGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2020
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular diseaseAna Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, et al.
Journal of Global Antimicrobial Resistance|January 30, 2025
Assessing the utilization of HIV genotype resistance testing: Insight from Italian Infectious Diseases UnitsAndrea De Vito, Antonia Bezenchek, Rossana Scutari, et al.
Antiviral Therapy|September 24, 2016
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohortAmedeo F Capetti, Gaetana Sterrantino, Maria V Cossu, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 26, 2020
Marked decrease in acquired resistance to antiretrovirals in latest years in ItalyAlessia Lai, Marco Franzetti, Annalisa Bergna, et al.
Pageof 20